Antifibrotic activity a fermentation filtrate of *Ganoderma lucidum*

Sang-Chul Kwon1, Yun-Bae Kim2*

1Food Safety Support Organization, Korea Food Industry Association, Seoul, Korea
2College of Veterinary Medicine, Chungbuk National University, Cheongju, Korea

The effects of a fermentation filtrate of *Ganoderma lucidum* (FGL) on carbon tetrachloride (CCl₄)-induced hepatic fibrosis were investigated in rats. Male Sprague-Dawley rats were orally administered with FGL (20 or 100 mg/kg) for 33 days, and orally administered with CCl₄ (1.0 mL/kg; 2 mL/kg of 50% in corn oil) at 3-day intervals 1 h after FGL treatment. Body and liver weights, blood and histopathological findings in accordance with hydroxyproline concentrations were analyzed. Chronic exposure to CCl₄ reduced the body weight gain, but increased liver weights and fibrosis, resulting in 3.35-fold increase in hydroxyproline level. Although FGL did not significantly reduce the CCl₄-induced body and liver weight changes, it attenuated the increases in the hepatic fibrosis and hydroxyproline contents. Taken together, it is suggested that FGL might prevent hepatic fibrosis, and that FGL or its ingredient could be a potential candidate for the prevention of chronic hepatic disorders.

**Key words:** Carbon tetrachloride (CCl₄), hepatic fibrosis, *Ganoderma lucidum*, fermentation filtrate

Hepatitis, a high incidence ailment in modern societies, is caused by hepatitis viruses, chronic alcohol intake, lipid peroxidative products and various drugs [1]. Chronic liver injury results in hepatic fibrosis and end stage cirrhosis. This is one of the major public health problems, related to life-threatening complications of portal hypertension, liver failure and finally increased incidence of hepatocellular carcinoma [2].

The relationship between oxidative damage and hepatocellular injury was observed in many previous studies showing strong hepatoprotective activities of antioxidative Oriental traditional herbs, such as *Scutellaria radix* [1], *Ginkgo biloba* [3] and *Ganoderma lucidum* (GL) [4]. GL, a traditional Oriental medicinal mushroom, has been widely used for the treatment of chronic hepatopathy of various etiologies with little or no side effects [5]. Polysaccharide and triterpenoid components in GL have been proposed as the bioactive constituents responsible for the protective activities against toxin- and ethanol-induced liver injuries [5,6]. It was also reported that triterpenoids and peptides isolated from GL protect against carbon tetrachloride (CCl₄)- and ω-galactosamine-induced hepatic injuries through its antioxidative and free radical-scavenging abilities [7-9]. In addition, we showed that culture extract of GL exerted anti-allergic and anti-atopic effects [10,11].

Notably, it is well known that fermentation of natural products leads to increases in active ingredients and to production of novel compounds. Based on the antioxidative, anti-inflammatory and anti-allergic, and acute hepatoprotective activities of GL, a fermentation filtrate of *Ganoderma lucidum* (FGL) was expected to improve chronic active hepatic fibrosis. In the present study, we investigate the antifibrotic effects of FGL in CCl₄-induced chronic hepatic fibrosis model.

Dried GL was minced, macerated, and adjusted to 25-30% precipitates by adding purified water. Into the homogenate, cultivated *Saccharomyces* (strain HM 2104) was added up to 4% and fermented at 45°C and pH 5.5 for 30-40 h. The crude culture precipitates were removed by centrifugation and microfiltration (pore size, 0.05 µm), and the alcohol produced during fermentation was fully removed in a vacuum evaporator [12].

*Corresponding author: Yun-Bae Kim, College of Veterinary Medicine and Research Institute of Veterinary Medicine, Chungbuk National University, 52 Naesudongro (Gaesin-dong), Cheongju, Chungbuk 361-763, Korea
Tel: +82-43-261-3358; FAX: +82-43-271-3246; E-mail: solar93@cbu.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Seven-week-old male Sprague-Dawley rats were orally administered with FGL (20 or 100 mg/kg) for 33 days, and, 1 h later, orally administered with CCl\textsubscript{4} at a dose of 1.0 mL/kg (50% in corn oil, 2 mL/kg) at 3-day intervals [13]. Body weights were recorded throughout the experimental period, and twenty four h after the final treatment, liver weights were measured. Liver tissues were fixed in 10% formalin, and paraffin-embedded sections (4 µm) were stained with hematoxylin-eosin for microscopic examination.

A part of liver tissue was homogenized in a 6 N HCl solution to make 3% homogenate, and boiled at 120°C for 20 min [14,15]. Into an aliquot (50 µL) of the homogenate, chloramine-T solution (400 µL) was added and incubated for 25 min at room temperature. Again, Ehrlich's solution (500 µL) was added, incubated in a 65°C water bath for 20 min, and the absorbance was read at 550 nm [13].

Data were expressed as the mean±SEM. Statistical analysis was performed using an analysis of variance (ANOVA) with the aid of SPSS for Windows v.10.0 (Chicago, Illinois, USA). A P value <0.05 was considered statistically significant.

CCl\textsubscript{4} (1.0 mL/kg) treatment at 3-day intervals decreased the body weight gain by 12%, which was attenuated by treatment with FGL in a dose-dependent manner (Figure 1). Especially, daily treatment with a high dose (100 mg/kg) of FGL recovered the CCl\textsubscript{4}-induced decrease in the body weight gain by 70%. In contrast to the decrease in the body weight gain, CCl\textsubscript{4} not only increased liver weight by 24%, but also enhanced the hydroxyproline contents to 3.35 folds control level (Table 1). The increased hydroxyproline content was confirmed by microscopic findings, exhibiting severe fibrosis (Figure 2). The liver weights increased by exposure to CCl\textsubscript{4} were attenuated by FGL in a dose-dependent manner, especially to the near-normal level in a high dose (100 mg/kg). Notably, the increased hydroxyproline contents were significantly recovered by FGL, in accordance with the microscopic observations.

In spite of tremendous strides in the modern medicine, there are not much drugs available for the treatment of liver disorders [16]. Liver fibrosis results from the fibrogenic activation of fibrocytes and hepatic stellate cells, called Ito cells, following continuous hepatocytic injury and cholestasis, sometimes leading to liver cirrhosis and hepatocellular carcinoma [2,17-19]. In the present study, repeated administration of CCl\textsubscript{4} also induced serious hepatic fibrosis, in parallel with the increased hydroxyproline contents [13]. Since oxidative stress is one of the most-causative factors...
of tissue fibrosis, the antifibrogenic effect of FGL was expected. Moreover, such effects also were inferred from that polysaccharides, triterpenoids and peptides of GL exerted protective effects against acute hepatic injury induced by toxins, CCl\textsubscript{4}, or D-galactosamine [5, 7-9]. More recently, it was demonstrated that an ethanol extract of GL suppressed thioacetamide-induced hepatic fibrosis by enhancing collagenase activity [20].

In the present preliminary study, FGL was confirmed to possess strong anti-fibrogenic activity. Although active ingredients and the action mechanisms remain to be clarified, it is suggested that FGL could be a potential candidate for the improvement of chronic hepatic disorders.

Acknowledgment

This work was supported by Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0094035).

References

1. Hwang JM, Tseng TH, Tsai YY, Lee HJ, Chou FP, Wang CJ, Chu CY. Protective effects of baicalein on tert-butyl hydroperoxide-induced hepatic toxicity in rat hepatocytes. J Biomed Sci 2005; 12(2): 389-397.
2. Zou Y, Yang Y, Li J, Li W, Wu Q. Prevention of hepatic injury by a traditional Chinese formulation, BJ-JN, in mice treated with Bacille-Calmette-Guérin and lipopolysaccharide. J Ethnopharmacol 2005; 107(3): 442-448.
3. Özenirler S, Dinçer S, Akyol G, Ozoğlu C, Oz E. The protective effect of Ginkgo biloba extract on CCl\textsubscript{4}-induced hepatic damage. Acta Physiol Hung 1997; 85(3): 277-285.
4. Lin JM, Lin CC, Chen MF, Ujiie T, Takada A. Radical scavenger and antipatophatic activity of Ganoderma formosanum, Ganoderma lucidum and Ganoderma neo-japonicum. J Ethnopharmacol 1995; 47(1): 33-41.
5. Gao YH, Huang M, Lin ZB, Zhou SF. Hepatoprotective Activity and the Mechanisms of Action of Ganoderma lucidum (Curt: Fr) P. Karst (Reishi mushroom) (Aphylloporomycetidae). Int J Med Mushrooms 2003; 5: 111-131.
6. Zhou CY, Jia W, Yang Y, Bai YQ. Experimental studies on prevention of several kinds of fungi polysaccharides against alcohol-induced hepatic injury. Edible Fungi 2002; 24: 36-37.
7. Wang MY, Liu Q, Che QM, Lin ZB. Effects of total Triterpenoids Extract from Ganoderma lucidum (Curt: Fr) P Karst (Reishi mushroom) on experimental liver injury models induced by carbon tetrachloride or D-galactosamine in mice. Acta Pharmaceut Sin 2000; 35: 326-329.
8. Sun J, He H, Xie BJ. Novel antioxidant peptides from fermented mushroom Ganoderma lucidum. J Agric Food Chem 2004; 52(21): 6646-6652.
9. Shi Y, Sun J, He H, Guo H, Zhang S. Hepatoprotective effects of Ganoderma lucidum peptides against D-galactosamine-induced liver injury in mice. J Ethnopharmacol 2008; 117(3): 415-419.
10. Kwon SC, Shin S, Jeon JH, Park D, Jang MJ, Kim JJ, Kim CH, Jeong JH, Kim YB. Anti-allergic effects of rose petal extract and Ganoderma lucidum culture on mast cell-mediated allergy model. Lab Anim Res 2008; 24: 93-97.
11. Jeon JH, Kwon SC, Park D, Shin S, Jang MJ, Joo SS, Kang H, Kim SH, Oh JY, Jeong JH, Kim YB. Effects of red and white rose petals and Ganoderma lucidum culture on ovalbumin-induced atopic dermatitis. Lab Anim Res 2008; 24(3): 347-354.
12. Jeon JH, Shin S, Park D, Jang JY, Choi BI, Kang JK, Joo SS, Hwang SY, Kim JC, Kim BY, Kim MR, Kim YB. Fermentation filtrates of Rubus coreanus relax the corpus cavernosum and increase sperm count and motility. J Med Food 2008; 11(3): 474-478.
13. Kim EJ, Shin S, Jang JY, Choi B, Park D, Jeon JH, Park JH, Hwang SY, Kim YB. Effects of Hwalgidan\textsuperscript{a} on hepatic injury induced by carbon tetrachloride in rats. Lab Anim Res 2007; 23(1): 59-67.
14. Fort J, Oberti F, Pilette C, Veal N, Gallois Y, Douay O, Rousselet MC, Rosenbaum J, Cäles P. Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology 1998; 28(6): 1525-1531.
15. Torozu K, Fujii E, Teruya S, Ogawa Y, Itou H, Suzuki M, Sugimoto T. Lobular difference in fibrotic changes in rat cirrhosis model induced by carbon tetrachloride. J Toxicol Pathol 2004; 17(4): 267-274.
16. Bhandarkar MR, Khan A. Antifibrotic effect of Nymphaea stellata willd., against carbon tetrachloride-induced hepatic damage in albino rats. J Ethnopharmacol 2004; 91(1): 61-64.
17. Sherlock S, Dooley J. Diseases of the Liver and Biliary System, 10th ed, Blackwell Science Press, Oxford, 1997; pp 303-384.
18. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis: definition nomenclature and classification. Bull World Health Organ 1977; 55(4): 521-540.
19. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 1978; 31(S): 395-414.
20. Wu YY, Fang HL, Lin WC. Post-treatment of Ganoderma lucidum reduced liver fibrosis induced by thioacetamide in mice. Phytother Res 2010; 24(4): 494-499.